Username Password
S&P 500: 1,317.82 Change: +0.03%

RAPTOR PHARMACEUTICAL CORP (RPTP)

Overview
Price 5.33
Price Change Today -$0.04 (-0.74%)
P&P rating Rating: 0
Zacks Rank 3 - HOLD
Open Price $5.34
Previous Close $5.37
Daily Range $5.30 - $5.40
52-Week Range $3.66 - $7.90
Volume 135,451
chart
Raptor Pharmaceutical Corp. is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it can have the greatest potential impact. Raptor currently has product candidates in clinical development designed to treat nephropathic cystinosis, non-alcoholic steatohepatitis (NASH), Huntington's Disease (HD), aldehyde dehydrogenase (ALDH2) deficiency, and a non-opioid solution designed to treat chronic pain and potentially thrombotic disorder. The company's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein (RAP) and related proteins that are designed to target cancer, neurodegenerative disorders and infectious diseases.
Other Resources for RPTP
zacks.com
Commentary
Zacks Blog: Zacks.com featured expert Kevin Matras highlights: Antares Pharma, Inc., Global Cash Access Holdings, Inc., InnerWorkings, Inc., Raptor Pharmaceuticals Corp. and TASER International, Inc.
November 22, 2011
Zacks Blog: Zacks Investment Ideas feature highlights: Intermune, Raptor Pharmaceutical and Transcept Pharmaceuticals
June 16, 2011
Raptor Pharmaceutical Corp. is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it can have the greatest potential impact. Raptor currently has product candidates in clinical development designed to treat nephropathic cystinosis, non-alcoholic steatohepatitis (`NASH`), Huntington's Disease (`HD`), aldehyde dehydrogenase (`ALDH2`) deficiency, and a non-opioid solution designed to treat chronic pain and potentially thrombotic disorder. The company's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein (`RAP`) and related proteins that are designed to target cancer, neurodegenerative disorders and infectious diseases.
 
Brokerage Analyst Recommendations
8 Brokerage Firms Covering RPTP
 
 
Strong Buy
8
Buy
0
Hold
0
Sell
0
Strong Sell
0
Average Broker Recommendation (ABR): 1
 
RPTP Ratings:BUY  SELL  HOLD
RPTP Consensus Forecasts
Rate this Stock!
You haven't rated this stock yet!

What The Community Thinks

Total Players

2 Buy
0 Sell
 
Top Buy Analysis
BUY: RPTP Rating: 0
Company: RAPTOR PHARMACEUTICL
Points: -25.86
Start Price: $7.39
Start Date: 02/05/2012 2:38 PM
StrongestStocks
StrongestStocks
P&P Score: 0.29
Recs:
Early in its new uptrend

Comments: 0 | Comment


Top Sell Analysis
No Sell Analysis. Be the First.
Blog Posts
No related Blog Posts.
Commentary
BUY: RAPTOR PHARMACEUTICL (RPTP)
Start Price: $7.39
Points: -25.86
Created: 02/05/2012
Early in its new uptrend

Comments: 0 | Comment

Recs:
 
BUY: RAPTOR PHARMACEUTICL (RPTP)
Start Price: $6.21
Points: -14.49
Created: 07/12/2011
Turning up from consolidation

Comments: 0 | Comment

Recs:
 
Picks
Username P&P Score Call Time Frame Start Date Start Price Today (change) Stock Gain S&P Gain Points Analysis
StrongestStocks 0.29 BUY Six Months to a Year 02/05/2012 $7.39 $5.33
(+0.19%)
-27.88% -2.01% -25.86 view
wallstreeter 0.23 BUY Six Months to a Year 07/12/2011 $6.21 $5.33
(+0.19%)
-14.17% +0.32% -14.49 view
Sponsored Links